Treeline Biosciences aspires to build transformative precision medicines for patients with cancer and other serious conditions.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 01/04/25 | $421,000,000 | |||
| 09/03/25 | $200,000,000 | Series A Extension |
AI Life Sciences Ajax Health ARCH Venture Partners Casdin Capital Exor Fidelity Management & Research Company GV KKR OrbiMed Advisors Rock Springs Capital T. Rowe Price Associates | undisclosed |
